Do the "oldest old" non-small cell lung cancer patients experience the worst outcomes after radiotherapy? Outcomes of Elderly NSCLC Patients
Main Article Content
Abstract
Background: Older patients with cancer tend to be denied curative treatment because of the perception that they may not be able to tolerate treatment, especially if they are aged ≥80 years.
Aim: We aimed to verify our hypothesis that patients aged ≥80 years who receive radiotherapy for non-small cell lung cancer fare better than their younger counterparts.
Methods and Materials: Medical records of all patients with non-small cell cancer who were referred to our institution for radiotherapy between January 1, 2006, and September 30, 2025, were reviewed. All eligible patients completed the planned curative radiotherapy. The patients were categorized into two age groups: <80 and ≥80 years. Toxicity and overall and progression-free survival were compared among age groups. Toxicity was divided into two groups: grades 0–2 or 3<. Multivariate analysis was performed using age, Charlson Scale score, sex, use of concomitant chemotherapy with radiotherapy, and adjuvant use of durvalumab as variables.
Results: Of the 528 patients, 470 completed radiotherapy. The age distribution was as follows: <80 years, 84% (n=395); and ≥80 years, 16% (n=75). No statistically significant difference in grade 3< toxicity was observed in the older age group. The chemoradiotherapy group had statistically significantly higher incidence rates of neutropenia (p<0.01) and esophagitis (p=0.02) compared with the radiotherapy monotherapy group. Moreover, the incidence rate of pneumonia was higher in the chemoradiotherapy (p=0.01) and adjuvant durvalumab (p=0.01) groups. Although the differences were not statistically significant, we observed higher trends in the incidence rates of thrombocytopenia in the older age (p=0.06) and chemoradiotherapy (p=0.10) groups compared with their counterparts, and neutropenia in male patients (p=0.07) compared with female patients. In the multivariate survival analysis, no statistically significant difference in overall survival was observed. However, the lower disease stage showed higher progression-free survival than the higher disease stage. There was a trend toward longer progression-free survival in the older age and adjuvant durvalumab groups (both p=0.08).
Conclusion: Compared with their younger counterparts, patients with non-small cell cancer aged ≥80 years showed no statistically significant differences in terms of faring even better after receiving radiotherapy for non-small cell cancer. However, these older patients showed trends of higher rates of severe thrombocytopenia and longer progression-free survival than younger patients. We could not verify our hypothesis; however, curative lung radiotherapy can be an effective and safe treatment for patients aged ≥80 years.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Ageing and health. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health (final access at Jan/2/2026)
3. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. doi: 10.1056/NEJMoa1709937
4. Lyengar P, Zhang-Velten E, Court L, et al. Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II/III non-small cell lung cancer and poor performance status. JAMA Oncol. 2021;7(10):1497-1505. doi: 10.1001/jamaoncol.2021.3186
5. Socinski MA, Özgüroğlu M, Villegas A, et al. Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage iii non–small–cell lung cancer (PACIFIC). Clin Lung Cancer. 2021; 22(6): 549-561.doi: 10.1016/j.cllc.2021.05.009
6. Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13(7):671-678. doi: 10.1016/S1470-2045(12)70139-0
7. Kravutske H, Mansoorian S, Käsmann L, et al. Real-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study. Acta Oncol. 2025;64:957-965. doi: 10.2340/ 1651-226X.2025.43496
8. Aoe K, Takigawa N, Hotta K, et al. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801. Eur J Cancer. 2014;50(16):2783-2790. doi: 10.1016/ j.ejca.2014.07.024
9. Zhang T, Bi N, Zhou Z, et al. The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy. J Thorac Dis. 2020;12(8):4347 -4356. doi: 10.21037/jtd-20-2137
10. Soni PD, Boonstra PS, Schipper MJ, et al. Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. J Thorac Oncol. 2017;12(3):539-546. doi: 10.1016/j.jtho.2016.11.2227
11. Driessen EJ, Bootsma GP, Hendriks LE, et al. Stage III non-small cell lung cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. Radiother Oncol. 2016;121(1):26–31. doi: 10.1016/ j.radonc.2016.07.025
12. Joo JH, Song SY, Kim SS, et al. Definitive radiotherapy alone over 60Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis. Radiat Oncol. 2015; 10:250. doi: 10.1186/s13014-015-0560-z
13. Zaborowska-Szmit M, Olszyna-Serementa M, Kowalski DM, Szmit S, Krzakowski M. Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy. Cancers (Basel). 2021;13(18):4534.doi: 10.3390/cancers13184534
14. Chen T, Zhou F, Jiang W, et al. Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients. J Thorac Dis. 2019;11(6): 2251-2266. doi: 10.21037/jtd.2019.06.24
15. Driessen EJM, Schulkes KJG, Dingemans AC, et al. Patterns of treatment and survival among older patients with stage III non-small cell lung cancer. Lung Cancer. 2018;116:55–61.doi: 10.1016/j.lungcan
16. Miller ED, Fisher JL, Haglund KE, et al. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol.2018;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135
17. Stinchcombe TE, Zhang Y, Vokes EE, et al. Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative group studies. J Clin Oncol. 2017;35(25):2885-2892. doi: 10.1200/JCO.2016.71.4758
18. Dawe DE, Christiansen D, Swaminath A, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016;99:180-185. doi: 10.1016/j.lun gcan.2016.07.016
19. Arulananda S, Mitchell P.Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. Transl Lung Cancer Res. 2018;7(Suppl 4):S388-S392. doi: 10.21037/tlcr.2018.08.12.
20. Park JE, Hong KS, Choi SH, et al. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients with Unresectable Stage III NSCLC: A Real-World Multicenter Study. Clin Lung Cancer. 2024;25(4):354-364. doi: 10.1016/j.cllc.2024.02.006
21. Kreinbrink P, Blumenfeld P, Tolekidis G, et al. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective. J Geriatr Oncol. 2017;8(5):351-355. doi: 10.1016/j.jgo.2017.07.002.
22. Videtic GMM, Woody NM, Reddy CA, Stephans KL. Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer. Pract Radiat Oncol. 2017;7(6):e543-e549. doi: 10.1016/j.prro.2017.06.011.
23. Shinde A, Li R, Kim J, Salgia R, Hurria A, Amini A. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin Oncol. 2018;45(4):210-219. doi: 10.1053/j.semino ncol.2018.06.002.
24. Bruno R, Poma AM, Panozzi M, et al. Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort. Cancers (Basel). 2024;16(7):1410. doi: 10.3 390/cancers16071410
25. Singareddy A, Flanagan ME, Samson PP, et al. Trends in Stage I Lung Cancer. Clin Lung Cancer. 2023;24(2):114-119. doi: 10.1016/j.cllc.2022.11.005.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi: 10.1016/0021-9681(87)90171-8
27. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682. doi: 10.1093/aje/kwq433
28. Zhou S, Zhang XH, Zhang Y, Gong G, Yang X, Wan WH. The Age-Adjusted Charlson Comorbidity Index Predicts Prognosis in Elderly Cancer Patients. Cancer Manag Res. 2022;14:1683-1691. doi: 10. 2147/CMAR.S361495
29. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0. Safety profier. national Cancer Insitute. https://safetyprofiler-ctep.nci.nih.gov/safety-profiler/index.html (final access Dec.28.2025).
30. Popescu T, Karlsson U, Vinh-Hung V, et al. Challenges facing radiation oncologists in the management of older cancer patients: Consensus of the International Geriatric Radiotherapy Group. Cancers (Basel). 2019;11(3):371. doi: 10.3390/ cancers11030371.